National Framework Agreement for Adalimumab Injection 1 April 2023

A Contract Award Notice
by NHS ENGLAND

Source
Find a Tender
Type
Framework (Goods)
Duration
not specified
Value
£1
Sector
HEALTH
Published
24 Mar 2023
Delivery
not specified
Deadline
n/a

Concepts

Location

United Kingdom: Please refer to Document No. 03, Schedule 8 in the ITO Documents for the list of Purchasing Points

Geochart for 1 buyers and 6 suppliers

1 buyer

6 suppliers

Description

Project Title: NHS National Framework Agreement for the supply of Adalimumab Injection commencing 1 April 2023 Offer reference number: CM/PHR/22/5660 CM/PHR/22/5660/01 - NHS Framework Agreement for the supply of Adalimumab Injection to South of England. Period of framework: 1 April 2023 to 31 August 2024 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 monthsCM/PHR/22/5660/02 - NHS Framework Agreement for the supply of Adalimumab Injection to the Midlands and East. Period of framework: 1 April 2023 to 28 February 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 monthsCM/PHR/22/5660/03 - NHS Framework Agreement for the supply of Adalimumab Injection to London. Period of framework: 1 April 2023 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 monthsCM/PHR/22/5660/04 - NHS Framework Agreement for the supply of Adalimumab Injection to North of England. Period of framework: 1 April 2023 to 28 February 2026 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months

Lot Division

1 CM/PHR/22/5660/01 - NHS Framework Agreement for the supply of Adalimumab

Lot 1 - CM/PHR/22/5660/01 - NHS Framework Agreement for the supply of Adalimumab Injection to South of England. Period of framework: 1 April 2023 to 31 August 2024 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
2 CM/PHR/22/5660/02 - NHS Framework Agreement for the supply of Adalimumab

Lot 2 - CM/PHR/22/5660/02 - NHS Framework Agreement for the supply of Adalimumab Injection to the Midlands and East. Period of framework: 1 April 2023 to 28 February 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
3 CM/PHR/22/5660/03 - NHS Framework Agreement for the supply of Adalimumab

Lot 3 - CM/PHR/22/5660/03 - NHS Framework Agreement for the supply of Adalimumab Injection to the London. Period of framework: 1 April 2023 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents
4 CM/PHR/22/5660/04 - NHS Framework Agreement for the supply of Adalimumab

Lot 4 - CM/PHR/22/5660/04 - NHS Framework Agreement for the supply of Adalimumab Injection to the North of England. Period of framework: 1 April 2023 to 28 February 2026 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Award Detail

1 Amgen (Cambridge)
  • Lot 2 - CM/PHR/22/5660/02 - NHS Framework Agreement for the supply of Adalimumab
  • Reference: 008624-2023-1
  • Value: £1
2 Sandoz (Surrey)
  • Lot 2 - CM/PHR/22/5660/02 - NHS Framework Agreement for the supply of Adalimumab
  • Reference: 008624-2023-2
  • Value: £1
3 Biogen (Maidenhead Berkshire)
  • Lot 2 - CM/PHR/22/5660/02 - NHS Framework Agreement for the supply of Adalimumab
  • Reference: 008624-2023-3
  • Value: £1
4 Abbvie (Berks)
  • Lot 2 - CM/PHR/22/5660/02 - NHS Framework Agreement for the supply of Adalimumab
  • Reference: 008624-2023-4
  • Value: £1
5 Fresenius Kabi (Cheshire)
  • Lot 2 - CM/PHR/22/5660/02 - NHS Framework Agreement for the supply of Adalimumab
  • Reference: 008624-2023-5
  • Value: £1
6 Celltrion Healthcare (Slough)
  • Lot 2 - CM/PHR/22/5660/02 - NHS Framework Agreement for the supply of Adalimumab
  • Reference: 008624-2023-6
  • Value: £1

Renewal Options

Option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months

Award Criteria

price _

CPV Codes

  • 33600000 - Pharmaceutical products

Indicators

  • Options are available.

Other Information

** PREVIEW NOTICE, please check Find a Tender for full details. **

Reference

Domains